Eli Lilly stops disclosing Phase 1 pipeline, prompting mixed reactions

Eli Lilly announced that it will no longer publicly share details of its Phase 1 drug candidates. The policy shift comes as the company’s GLP-1 product continues to generate the highest sales among medicines and its market capitalization surpasses other healthcare firms.

Analysts and industry observers have offered mixed opinions. Some view the move as a strategic effort to protect competitive information, while others worry it reduces transparency for investors and partners.

The change does not affect the company’s ongoing clinical programs, but it marks a notable departure from the usual practice of reporting early-stage research activity.

Lilly has not provided a timeline for when, if ever, it might resume public updates on its Phase 1 portfolio.